Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).
暂无分享,去创建一个
R. Greil | A. Ganser | A. Hinke | T. Decker | F. Kauff | B. Hertenstein | W. Knauf | W. Willenbacher | K. Chow | M. Rummel | R. Weide | M. Heike | M. Koenigsmann | C. Losem | A. Burchardt | E. Lange | M. Goerner | J. Barth | C. A. Lerchenmuller | T. Gaska